LILLY ENDOWMENT INC

Lilly Endowment Inc filed a single-line 13F as of Q1 2026: exactly one position, Eli Lilly and Company, valued at $84.5B — representing 100% of the reported book. This is an extreme-concentration filing pattern that contradicts the diversified endowment stereotype, but it reflects the fund's actual operating model: large, long-duration philanthropic endowment with a concentrated equity sleeve rather than a broadly diversified institutional portfolio. The Lilly bet is specifically on Eli Lilly's GLP-1 and Alzheimer's drug pipelines (Mounjaro/Zepbound and donanemab) which drove the stock's multi-year appreciation and which Lilly Endowment has held through successive concentration builds. At $84.5B single-name, the filing's market-signal content is primarily that the endowment has not moderated its concentration despite the company's market-cap appreciation into 2026 — a statement of continued conviction rather than portfolio rebalancing.